Projects per year
Personal profile
Research interests
Dr. Jong Yun's work focuses on the development of sphingosine kinase (SphK) inhibitors as anti-cancer therapeutic agents.
The Yun research group is currently pursuing three separate projects that are centered around the development of therapeutic agents that specifically target SphK.
The first project, target identification, combines biochemistry and cell and molecular biology techniques to determine the signaling mechanisms associated with the functional role of SphK in normal and cancerous cells.
The second project, target validation, is closely associated with the physiological and/or pathological functions of SphK. To validate SphK as a therapeutic target, the lab currently has ongoing studies in collaboration with other investigators including clinicians such as oncologists and pathologists.
The third project, proof-of-concept studies, centers around the development of novel disease-specific and effective therapeutic approaches by targeting SphK. In this regard, Dr. Yun's work has already identified and refined novel SphK inhibitors (SKIs) by screening libraries of synthetic compounds. Currently, the lab has several ongoing proof-of-concept studies in collaboration with other investigators who have expertise medicinal chemistry, computational chemistry and in vivo mouse model systems.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 1 Finished
-
Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases
Kale, V. P., Hengst, J. A., Sharma, A. K., Golla, U., Dovat, S., Amin, S. G., Yun, J. K. & Desai, D. H., Aug 2023, In: Pharmaceuticals. 16, 8, 1060.Research output: Contribution to journal › Article › peer-review
Open Access -
Inhibition of Sphingosine Kinase Activity Enhances Immunogenic Cell Surface Exposure of Calreticulin Induced by the Synthetic Cannabinoid 5-epi-CP-55,940
Hengst, J. A., Nduwumwami, A. J., Raup-Konsavage, W. M., Vrana, K. E. & Yun, J. K., Oct 1 2022, In: Cannabis and Cannabinoid Research. 7, 5, p. 637-647 11 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Regulatory Role of Sphingosine-1-Phosphate and C16:0 Ceramide, in Immunogenic Cell Death of Colon Cancer Cells Induced by Bak/Bax-Activation
Hengst, J. A., Nduwumwami, A. J. & Yun, J. K., Nov 2022, In: Cancers. 14, 21, 5182.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Sphingosine kinase inhibition enhances dimerization of calreticulin at the cell surface in mitoxantrone-induced immunogenic cell death
Nduwumwami, A. J., Hengst, J. A. & Yun, J. K., Sep 1 2021, In: Journal of Pharmacology and Experimental Therapeutics. 378, 3, p. 300-310 11 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA)
Hengst, J. A., Dick, T. E., Smith, C. D. & Yun, J. K., Sep 1 2020, In: Cancer Biology and Therapy. 21, 9, p. 841-852 12 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations
Prizes
-
Outstanding Collaborative Research Team
Adair, James Hansell (Recipient), Amin, Shantu (Recipient), Claxton, David (Recipient), Desai, Dhimant (Recipient), Hengst, Jeremy (Recipient), Liao, Jiangang "Jason" (Recipient), Paulson, Robert (Recipient), Sharma, Arun (Recipient), Stanley, Bruce (Recipient), Wang, Hong-Gang (Recipient), Yun, Jong (Recipient) & Zhu, Junjia (Recipient), 2015
Prize